why choose us

First received: December 20, 2022

Clinical Trial: GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

Study Status: Completed

Recruit Status: RECRUITING

Condition: Glioblastoma

Study Type: OBSERVATIONAL


Official Title: A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)

Brief Summary: The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.

Read more